4-((3-(trifluoromethyl)benzyl)oxy)piperidine | 81151-55-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((3-(trifluoromethyl)benzyl)oxy)piperidine
• 英文别名: 4-[[3-(Trifluoromethyl)phenyl]methoxy]piperidine
• CAS: 81151-55-5
• 化学式: C₁₃H₁₆F₃NO
• mdl: MFCD11547097
• 分子量: 259.271
• InChiKey: MPARZOFPWOKMBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-bromo-1-isopentyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 、 4-((3-(trifluoromethyl)benzyl)oxy)piperidine 在 2-(2^'-di-tert-butylphosphine)biphenylpalladium(II) acetate potassium phosphate 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 以87%的产率得到1-(3-Methylbutyl)-2-oxo-4-[4-[[3-(trifluoromethyl)phenyl]methoxy]piperidin-1-yl]pyridine-3-carbonitrile
  参考文献：
  名称：

  WO2007/104783

  摘要：

  公开号：

文献信息

• [EN] ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN<br/>[FR] DÉRIVÉS D'ARYLCARBOXAMIDE EN TANT QU'INHIBITEURS DE CANAL SODIQUE POUR LE TRAITEMENT DE LA DOULEUR
  申请人：AMGEN INC

  公开号：WO2011103196A1

  公开（公告）日：2011-08-25

  The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了一种抑制电压门控钠通道（Nav）的化合物，特别是Nav 1.7，因此适用于治疗通过抑制这些通道可治疗的疾病，特别是慢性疼痛疾病。还提供了含有这种化合物的药物组合物以及制备这种化合物的方法。
• CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS
  申请人：Bregman Howard

  公开号：US20130131035A1

  公开（公告）日：2013-05-23

  The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了一种抑制电压门控钠通道（Nav）的化合物，特别是Nav 1.7，因此可用于治疗可通过抑制这些通道治疗的疾病，特别是慢性疼痛疾病。还提供了含有这种化合物的药物组合物以及制备这种化合物的方法。
• From dopamine 4 to sigma 1: Synthesis, SAR and biological characterization of a piperidine scaffold of σ1 modulators
  作者：Kirsten T. Tolentino、Viktoriya Mashinson、Manish K. Sharma、Yashpal S. Chhonker、Daryl J. Murry、Corey R. Hopkins

  DOI：10.1016/j.ejmech.2022.114840

  日期：2022.12

  The sigma 1 receptor is a multifunctional receptor with wide distribution in the nervous system and its function has been implicated with a number of neurological disorders including dementia and Alzheimer's disease (AD) and other neurodegenerative disorders. In addition, modulators of σ1 have been advanced into clinical trials for the treatment of pain. Starting from our previously disclosed piperidine

  σ1 受体是一种广泛分布于神经系统的多功能受体，其功能与许多神经系统疾病有关，包括痴呆和阿尔茨海默氏病 (AD) 以及其他神经退行性疾病。此外，σ1 调节剂已进入治疗疼痛的临床试验。从我们之前公开的哌啶支架开始，我们已经确定了一类有效的 sigma 1 调节剂。这项工作突出了导致 D 4和 σ1 活动差异的关键 SAR 组件。此外，我们进一步分析了一组体外和体内的脱靶受体中的先导化合物药代动力学研究。这最终导致发现了多种 σ1 受体调节剂，这些调节剂具有允许在动物模型中进行研究的特性。
• 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors
  申请人：Ortho-McNeil-Janssen Pharmaceuticals, Inc.

  公开号：EP2426125A1

  公开（公告）日：2012-03-07

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是符合式 (I) 的新型吡啶酮衍生物 其中所有基团在申请和权利要求中均有定义。根据本发明的化合物是代谢受体-亚型 2（"mGluR2"）的正异位调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及涉及代谢受体的 mGluR2 亚型的疾病。特别是，这类疾病是选自焦虑症、精神分裂症、偏头痛、抑郁症和癫痫组的中枢神经系统疾病。本发明还涉及药物组合物和制备此类化合物及组合物的工艺，以及使用此类化合物预防和治疗涉及 mGluR2 的此类疾病。
• Discovery and characterization of benzyloxy piperidine based dopamine 4 receptor antagonists
  作者：Kirsten T. Tolentino、Viktoriya Mashinson、Anish K. Vadukoot、Corey R. Hopkins

  DOI：10.1016/j.bmcl.2022.128615

  日期：2022.4